Patents by Inventor Xiaoxing HUANG

Xiaoxing HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11933724
    Abstract: Disclosed are a device of complex gas mixture detection based on optical-path-adjustable spectrum detection and a method therefor, and the device includes: a light source configured for generating an incident beam and emitting the incident beam into an optical gas cell; the optical gas cell, including a cavity configured for accommodating a gas sample, and a reflection module group configured for reflecting the incident beam and a track arranged in the cavity, where the track is consistent with a light path of the light beam in the cavity; a detector module that is connected with the track in a relatively movable manner and is configured for receiving light beams and obtaining spectral data, where an optical path is changed by moving the detector module relative to the track; and a data acquisition unit that is configured for acquiring the spectral data obtained by the detector module.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: March 19, 2024
    Assignee: Hubei University of Technology
    Inventors: Yin Zhang, Xiaoxing Zhang, Ran Zhuo, Zhiming Huang, Guozhi Zhang, Dibo Wang, Shuangshuang Tian, Mingli Fu, Yunjian Wu, Yan Luo, Shuo Jin, Jinyu Pu, Yalong Li
  • Patent number: 11471503
    Abstract: Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 18, 2022
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiaoxing Huang, Guoqing Cao, Changyong Yang, Lianshan Zhang
  • Publication number: 20220251203
    Abstract: The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.
    Type: Application
    Filed: November 5, 2019
    Publication date: August 11, 2022
    Inventors: Lianshan Zhang, Qing Yang, Quanren Wang, Xiaoxing Huang, Cheng Liao, Changyong Yang, Dingwei Ye, Xiaohua Wu
  • Patent number: 11078213
    Abstract: The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: August 3, 2021
    Assignee: HONGYUN BIOTECH CO., LTD.
    Inventors: Xianming Deng, Baoding Zhang, Shuang Liu, Chao Dong, Xihuan Sun, Xiaoxing Huang, Zhou Deng, Yunzhan Li, Yue Lu, Li Li, Zhiyu Hu
  • Publication number: 20200368309
    Abstract: Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description.
    Type: Application
    Filed: December 5, 2018
    Publication date: November 26, 2020
    Inventors: Xiaoxing HUANG, Guoqing CAO, Changyong YANG, Lianshan ZHANG
  • Publication number: 20200207779
    Abstract: The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 2, 2020
    Applicant: HONGYUN BIOTECH CO., LTD.
    Inventors: Xianming DENG, Baoding ZHANG, Shuang LIU, Chao DONG, Xihuan SUN, Xiaoxing HUANG, Zhou DENG, Yunzhan LI, Yue LU, Li LI, Zhiyu HU
  • Patent number: 10508118
    Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 17, 2019
    Assignee: Xiamen University
    Inventors: Xianming Deng, Zhongji Zhuang, Zhou Deng, Xiaoxing Huang, Yan Liu, Ting Zhang, Wei Huang, Qingyan Xu, Zhiyu Hu
  • Publication number: 20190211030
    Abstract: The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 11, 2019
    Applicant: HONGYUN BIOTECH CO., LTD.
    Inventors: Xianming DENG, Baoding ZHANG, Shuang LIU, Chao DONG, Xihuan SUN, Xiaoxing HUANG, Zhou DENG, Yunzhan LI, Yue LU, Li LI, Zhiyu HU